Publications by authors named "Stevan Shaw"

Claim this Profile
H
Human spinal enthesis comparative biology of IL-17F and IL-17A reveals greater T-cell IL-17F induction and IL-23 regulation.
Nicole McDermott, Ala Altaie, Tom Macleod, Charlie Bridgewood, Peter Loughenbury, Stevan Shaw

Front Immunol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples.
Joseph Rastrick, Hannah Edwards, Alex S Ferecskó, Gaëlle Le Friec, Avneet Manghera, Stevan Shaw

Br J Dermatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition.
Ralph Adams, Christopher G Bunick, Alastair D G Lawson, Braulio Gomez, Stevan Shaw

J Invest Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging.
Xenofon Baraliakos, Jerney de Jongh, Denis Poddubnyy, Gerben J C Zwezerijnen, Robert Hemke, Stevan Shaw

Ther Adv Musculoskelet Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab for the treatment of psoriatic arthritis.
Yoshiya Tanaka, Stevan Shaw

Expert Rev Clin Immunol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential regulation of IL-17A and IL-17F via STAT5 contributes to psoriatic disease.
Suzanne Cole, Avneet Manghera, Lachrissa Burns, Janine Barrett, Nicole Yager, Stevan Shaw

J Allergy Clin Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Sophie Glatt, Gregor B E Jemec, Seth Forman, Christopher Sayed, George Schmieder, Stevan Shaw

JAMA Dermatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin (IL)-12 and IL-18 Synergize to Promote MAIT Cell IL-17A and IL-17F Production Independently of IL-23 Signaling.
Suzanne Cole, Janine Murray, Catherine Simpson, Remi Okoye, Kerry Tyson, Stevan Shaw

Front Immunol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F.
Ralph Adams, Asher Maroof, Terry Baker, Alastair D G Lawson, Ruth Oliver, Stevan Shaw

Front Immunol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin 17A and IL-17F Expression and Functional Responses in Rheumatoid Arthritis and Peripheral Spondyloarthritis.
Sijia Chen, Iris C Blijdorp, Leonieke J J van Mens, Rowann Bowcutt, Talia E Latuhihin, Stevan Shaw

J Rheumatol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases.
Sijia Chen, Ross Paveley, Lianne Kraal, Lathees Sritharan, Elizabeth Stevens, Stevan Shaw

J Autoimmun· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells.
Mittal Shah, Asher Maroof, Panos Gikas, Gayatri Mittal, Richard Keen, Stevan Shaw

RMD Open· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.
Sophie Glatt, Peter C Taylor, Iain B McInnes, Georg Schett, Robert Landewé, Stevan Shaw

Ann Rheum Dis· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Bryan Smith, Andrea Kiessling, Rocio Lledo-Garcia, Kate L Dixon, Louis Christodoulou, Sophie P Shaw, Stevan Shaw

MAbs· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of an Inhaled IL-13 Antibody Fragment in a Model of Chronic Asthma.
Daniel Lightwood, Markus Tservistas, Monique Zehentleitner, Kaushik Sarkar, Alison Turner, Stevan Shaw

Am J Respir Crit Care Med· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
Sophie Glatt, Dominique Baeten, Terry Baker, Meryn Griffiths, Lucian Ionescu, Stevan Shaw

Ann Rheum Dis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
Sophie Glatt, Eric Helmer, Birgit Haier, Foteini Strimenopoulou, Graham Price, Stevan Shaw

Br J Clin Pharmacol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
Anthony Shock, Linda Burkly, Ian Wakefield, Christopher Peters, Ellen Garber, Stevan Shaw

Arthritis Res Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling.
Stevan Shaw, Tim Bourne, Chris Meier, Bruce Carrington, Rich Gelinas

MAbs· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collagen II antibody-induced arthritis in Tg1278TNFko mice: optimization of a novel model to assess treatments targeting human TNFα in rheumatoid arthritis.
Adrian Richard Moore, Sarah Allden, Tim Bourne, Maria C Denis, Ksanthi Kranidioti, Stevan Shaw

J Transl Med· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.
Kosmas Kretsos, Georg Golor, Astrid Jullion, Matthew Hickling, Suzanne McCabe, Stevan Shaw

Clin Pharmacol Drug Dev· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis.
Emily Gwyer Findlay, Lynett Danks, Jodie Madden, Mary M Cavanagh, Kay McNamee, Stevan Shaw

Proc Natl Acad Sci U S A· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury.
Mesias Pedroza, Daniel J Schneider, Harry Karmouty-Quintana, Julie Coote, Stevan Shaw

PLoS One· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel mutation in CD83 results in the development of a unique population of CD4+ T cells.
Leon F García-Martínez, Mark W Appleby, Karen Staehling-Hampton, Dawn M Andrews, Yuching Chen, Stevan Shaw

J Immunol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis